ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMA-targeted radioligand therapy applicability.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer with limited treatment approaches. Prostate-specific membrane antigen (PSMA), widely applied as a target for molecular imaging and radioligand therapy of prostate cancer, demonstrates the highest expression in TNBC across all molecular subtypes of breast cancer, and represents a promising target for imaging and treatment of TNBC patients.
methodsThis prospective study included 20 patients with metastatic TNBC who underwent both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Qualitative and quantitative image analysis was performed to determine the uptake predominance of one of the tracers and the added value of the diagnostic CT, as well as to assess the potential applicability of PSMA-targeted radioligand therapy (PSMA-RLT).
resultsA total of 229 lesions were identified using both [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT. Concordant and discordant lesions were observed for both tracers, with a greater number of discordant lesions identified by [¹⁸F]PSMA-1007. [¹⁸F]FDG demonstrated higher uptake in TNBC lesions. An exception was observed in lung lesions, where no significant difference was found between tracers. The application of diagnostic CT revealed additional TNBC lesions that were not identified by PET, for each tracer. None of the patients demonstrated a [¹⁸F]PSMA-1007 uptake level sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used.
conclusionDespite detectable [¹⁸F]PSMA-1007 uptake in TNBC lesions, [¹⁸F]FDG uptake was generally higher. Furthermore, the diagnostic CT can identify additional PET-negative lesions. Although PSMA expression is confirmed in TNBC, it may be insufficient to provide potential benefit from PSMA-RLT for this patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.